Top-Rated StocksTop-Rated Most-Upgraded StocksMost-Upgraded

NYSE:BSX

Boston Scientific (BSX) Stock Forecast, Price & News

$53.37

+1.27 (+2.44%)

(As of 09/28/2023 ET)

Compare

Today's Range: $52.14
▼
$53.50
50-Day Range: $50.19
▼
$54.68
52-Week Range: $38.54
▼
$55.38

Volume: 6.58 million shs
Average Volume: 8.06 million shs
Market Capitalization: $78.15 billion

P/E Ratio: 88.95
Dividend Yield: N/A
Price Target: $60.10

Boston Scientific MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 12.6% Upside
$60.10 Price Target
Short Interest: Healthy
0.81% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -1.10
Upright™ Environmental Score
News Sentiment: 0.58
Based on 33 Articles This Week
Insider Trading: Selling Shares
$11.57 M Sold Last Quarter
Proj. Earnings Growth: 12.06%
From $1.99 to $2.23 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.92 out of 5 stars

Medical Sector

44th out of 969 stocks

Surgical & Medical Instruments Industry

8th out of 100 stocks

3.5

Analyst's Opinion

Consensus Rating
Boston Scientific has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 15 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $60.10, Boston Scientific has a forecasted upside of 12.6% from its current price of $53.37.
Amount of Analyst Coverage
Boston Scientific has been the subject of 12 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

4.0

Short Interest

Percentage of Shares Shorted
0.81% of the outstanding shares of Boston Scientific have been sold short.
Short Interest Ratio / Days to Cover
Boston Scientific has a short interest ratio ("days to cover") of 1.6, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Boston Scientific has recently decreased by 2.78%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Boston Scientific does not currently pay a dividend.
Dividend Growth
Boston Scientific does not have a long track record of dividend growth.

4.1

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Boston Scientific has received a 57.53% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Medical monitors for cardiac surgery", "Cardiac resynchronization therapy (CRT) devices", "Surgical instruments for cardiac operations", "Wound closure devices", "Medical endoscopes", and "Coronary stents" products. See details.
Environmental Sustainability
The Environmental Impact score for Boston Scientific is -1.10.

3.1

News and Social Media Coverage

News Sentiment
Boston Scientific has a news sentiment score of 0.58. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 33 news articles for Boston Scientific this week, compared to 20 articles on an average week.
Search Interest
40 people have searched for BSX on MarketBeat in the last 30 days. This is an increase of 74% compared to the previous 30 days.
MarketBeat Follows
14 people have added Boston Scientific to their MarketBeat watchlist in the last 30 days. This is an increase of 75% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Boston Scientific insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $11,566,176.00 in company stock.
Percentage Held by Insiders
Only 0.71% of the stock of Boston Scientific is held by insiders.
Percentage Held by Institutions
89.11% of the stock of Boston Scientific is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

2.5

Earnings and Valuation

Earnings Growth
Earnings for Boston Scientific are expected to grow by 12.06% in the coming year, from $1.99 to $2.23 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Boston Scientific is 88.95, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 124.10.
Price to Earnings Ratio vs. Sector
The P/E ratio of Boston Scientific is 88.95, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 151.41.
Price to Earnings Growth Ratio
Boston Scientific has a PEG Ratio of 2.07. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Boston Scientific has a P/B Ratio of 4.35. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Boston Scientific (NYSE:BSX) Stock

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through MedSurg and Cardiovascular segments. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, that uses in the treatment of coronary artery disease and aortic valve conditions. Further, it provides stents, balloon catheters, guidewires, atherectomy, and thrombectomy systems to treat arterial and venous diseases; and peripheral embolization devices, radioactive microspheres, cryotherapy ablation systems, and micro and drainage catheters to treat cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.

BSX Price History

30 days | 90 days | 365 days | Advanced Chart

BSX Stock News Headlines

August 30, 2023 | marketbeat.com

A Significant Reversal is in Sight for These 5 Med Tech Companies (BSX)

Med tech stocks are down YOY despite strong secular tailwinds, cash flow, and dividends; the downturn in action is an opportunity and reversal is at hand.

August 29, 2023 | marketbeat.com

5 Good Reasons it's Time to Buy High-Yield Dividend King 3M (BSX)

3M settled the ear plug lawsuit, clearing the path forward. The stock offers investors a high yield and value that may be too hard to pass up

September 29, 2023 | Weiss Ratings (Ad)

Overlooked AI Stock Gets Urgent "Buy"

We issued our first "Buy" rating on Apple when it traded at the equivalent of 56 cents per share. It's up 32,571% since. And while Nvidia is up 3x this year… We called it back in 2011. And it has surged 97x (9,624% to be exact) since then. Now, our Weiss Ratings has issued a "Buy" on a stock that's leading the AI revolution in one of the most profitable industries.

September 27, 2023 | benzinga.com

Here's How Much $100 Invested In Boston Scientific 15 Years Ago Would Be Worth Today

September 27, 2023 | finance.yahoo.com

Boston Scientific: Encouraging and Empowering Tomorrow’s STEM Pioneers

September 26, 2023 | finance.yahoo.com

Is Boston Scientific (BSX) Outperforming Other Medical Stocks This Year?

September 26, 2023 | msn.com

From stage in Boston, boygenius announces new EP

September 26, 2023 | americanbankingnews.com

Boston Scientific Co. (NYSE:BSX) Receives Consensus Recommendation of "Buy" from Brokerages

September 29, 2023 | Tradewins (Ad)

Successful Options Trading Begins With…

Options trading expert Wendy Kirkland’s free guide reveals the options trading principles that are as easy to implement as they are to learn and how using them could earn you thousands in extra income each month!

September 26, 2023 | americanbankingnews.com

Brokerages Set Boston Scientific Co. (NYSE:BSX) PT at $60.10

September 25, 2023 | finance.yahoo.com

The Zacks Analyst Blog Highlights Amazon.com, Boeing, Regeneron, Boston Scientific and Waste Management

September 25, 2023 | msn.com

Boston Scientific (BSX) Set to Acquire Relievant Medsystems

September 25, 2023 | americanbankingnews.com

Boston Scientific Co. (NYSE:BSX) Expected to Post Q1 2025 Earnings of $0.65 Per Share

September 24, 2023 | americanbankingnews.com

Barclays Increases Boston Scientific (NYSE:BSX) Price Target to $60.00

September 24, 2023 | americanbankingnews.com

Boston Scientific Co. (NYSE:BSX) EVP Sells $872,685.00 in Stock

September 23, 2023 | msn.com

UBS Maintains Boston Scientific (BSX) Buy Recommendation